Inflammatory bowel disease patients (IBD) are more likely to suffer from mental disorders, malnutrition and poor quality of life (QoL), all of which can result in poor clinical outcomes. The aim of this study is to find out how common malnutrition, psychiatric difficulties and poor quality of life is in IBD patients, as well as their risk factors and evaluation of the activity of Alkaline Phosphatase (ALP), Alanine Transaminase (ALT), and Aspartate Aminotransferase (AST), with measuring the level of urea and creatinine. The mean +/- SD of age for the three groups (CD, UC and HC) were 27.02 +/- 7.71, 29.12 +/- 7.82 and 30.58 +/- 7.30 years respectively; ALT in the sera of both patient groups (CD&UC) was a significant decrease (p<0.05) when compared to the (HC group) while significant decrease (p<0.05) in AST in (CD group), as well as highly significant increase (p<0.001) in AST of (UC group) was discovered when compared to their levels in the matching (HC group). A highly significant increase (p<0.001) in serum ALP of (UC group) and a significant increase ( p<0.05) of (CD) group in comparison to that of the (HC group), and a nonsignificant differences (p<0.05) in serum Urea and Creatinine of both patient groups (CD & UC) were discovered when compared to that of the (HC group). It was concluded that the psychological state could be one of the reasons for the occurrence of inflammatory bowel disease (IBD) which has a poor impact on QoL.
The results of regional anesthesia (RA) techniques on pain relief and narcotic consumption are challenging and should be evaluated. Hence, the purpose of the present article was to evaluate the efficacy and outcome of RA in adult patients with burns to decrease narcotic consumption and pain. The initial search was performed by two blind and independent browsers in electronic databases (PubMed, Cochrane Library, and Embase) until May 2021. For data analysis, after extracting the data of three studies that met the inclusion criteria, the mean and risk difference methods were used with a 95% confidence interval, the fixed-effect model and the Mantel-Haenszel/inverse variance method were used were calculated for the data. Stata software version 16, a faster version of Stata, was used for statistical analysis. 24 articles were found in the initial review, the abstracts reviewed by two blind and independent authors. Finally, after reviewing the full text of 9 articles, 3 articles were selected. The mean difference of cumulative Morphine requirements was 49.01 (MD, -49.01 95% CI 56.36, -41.67. P-VALUE=0.00) between continuous RA and control group of cumulative Morphine requirements. Meta-analysis showed that both RA had statically significantly lower total morphine consumption than the control group. Meta-analysis showed RA reduced total morphine consumption and pain.
The assessment of Ciprofloxacin.HCI using continuous flow injection diverging light was investigated. A moder, simple, rapid, and sensitive approach has been developed by using an ISNAG-Fluorimeter analyzer for assessing Ciprofloxacin.HCI pure state as well as pharmaceuticals (tablets); the process was based on the interaction of Ciprofloxacin.HCI with ammonium metavanadate (v) (AMV) as a precipitating agent to yield an ion pair association yellow precipitate rapidly in salt medium. To increase the affectability of the established approach, optimum parameters have been selected. For the instrument response vs Ciprofloxacin-HCl concentrations, the scatter plot range and linear dynamic range were 0.0-50 mmol/L. For linear dynamic range, the correlation coefficient (r) was 0.98623, and the percentage linearity (R-2 percent) was 97.26%. With a concentration of 10, 35 mmol/L, the percentage linearity for repeatability (n=8) was less than 0.34 percent. The detection limit of gradual dilution for the lowest concentration in the scatter plot range of the calibration curve was 0.221 g/sample. Ciprofloxacin.HCI in pharmaceutical tablets was effectively estimated using the described approach. The individual t-test with 95 percent confidence (alpha=0.05) was used to analyze drugs using the usual incremental technique. The results were also compared to those obtained using traditional UV-Spectrophotometric techniques at a wavelength of 272 nm. The ISNAG-Fluorimeter analyzer and traditional techniques yielded no significant differences in the results.
Novel N,N-bidentate azo ligand, namely 8-[5-(2-sulfonic acid naphthyl)azo]Caffeine (SNAC), as well as their metal complexes with [Ag(I), Co(II), Cu(II), Pd(II),and Pt(IV)] were synthesized and characterized by utilizing elemental analysis, spectroscopic techniques, magnetic susceptibility, molar conductance and thermal analysis. The stability constant and Gibbs free energy were examined by spectroscopic methods. The ligand( SNAC) in comparison to its complexes were tested for their antibacterial, antioxidant, anticancer and burn healing activities.
Atorvastatin (ATO) with its chemical formula of (C33H35FN2O5) is one of the cholesterol-lowering drugs that can also reduce hematoma volume (HV). Considering the importance of pharmacological treatments in improving the patient condition, the aim of this study was to evaluate the ATO effect on chronic subdural hematoma (CSDH) status. In this systematic review (SR) study, all articles about the ATO effect on CSDH status were entered into a study, without time constraints, by two authors who were professional in SR articles. In the initial search, 176 articles were found, of which 73 articles were deleted due to duplicate records, and after further review and removal of unrelated articles, this number reduced to 11 articles, and systematic review data was reported with 11 articles. In all articles, radiological clinical findings were used to diagnose hematoma. In most of the reviewed articles, atorvastatin was effective in reducing subdural hemorrhage. The articles ranged from 2014 to 2021, the total sample size was 1278 patients and the follow-up period varied from 2 months to 4 years. Concerning the ATO effect in reducing HV status in CSDH patients, it is recommended to prescribe this drug to improve HV levels.
